Feb 22, 2017 at OncLive

Nivolumab Improves Survival in Advanced Gastric/GEJ Cancer

By : OncLive

At the 2017 Gastrointestinal Cancers Symposium, researchers presented the exciting new study that treatment with nivolumab (Opdivo) reduces the risk of death by 37% for patients with advanced gastric or gastroesophageal junction (GEJ) cancer following second or later-line chemotherapy. 

Read More
Feb 21, 2017 at MedPage Today

Older Patients with GI Cancers Don’t Always Receive Tx

By : MedPage Today

New research shows older patients with unresected gastric cancer benefit from treatment, but many often do not receive cancer-specific therapy.

Read More
Feb 17, 2017 at Washington University School of Medicine in St. Louis

New insight into origin of stomach cancer

By : Washington University School of Medicine in St. Louis

In a mouse model, researchers found that damage to acid-secreting cells alone doesn’t jump-start the transformation of healthy cells into precancerous cells. This could provide new insights into origin of stomach cancer.

Read More
Feb 16, 2017 at Oncology Nurse Advisor

Second-line Weekly Nab-paclitaxel Noninferior to Paclitaxel for Gastric Cancer

By : Oncology Nurse Advisor

New research out of The Lancet Gastroenterology & Hepatology journal shows that weekly nab-paclitaxel was noninferior to weekly solvent-based paclitaxel as second-line treatment for patients with advanced gastric cancer.

Read More
Feb 15, 2017 at MDLinx

Chemotherapy and survival benefit in elderly patients with advanced gastric cancer

By : MDLinx

A new scoring system developed to help clinicians assess whether elderly patients would benefit from chemo was presented at ASCO’s 2017 Gastrointestinal Cancers Symposium. Check it out and other abstracts shared at the conference here.

Read More
SHARE